Chromosomal translocations affecting band 3q27, where BCL6 gene is located, are among the most common genetic abnormalities in non-Hodgkin's lymphoma of B-cell type (B-NHL). The BCL6 gene encodes a BTB/ POZ zinc finger transcription factor, which exerts repressive activity by recruiting corepressor molecules. The 3q27/BCL6 translocation is unique in that it can involve not only immunoglobulin (Ig) genes but also non-Ig chromosomal loci as a partner. To date, around 20 non-Ig partner genes have been identified. As a result of non-Ig ; BCL6 translocations, many types of regulatory sequences of each partner gene substitute for the 5′ untranslated region of BCL6, and the rearranged BCL6 comes under the control of the replaced promoter. The introduction of non-Ig ; BCL6 constructs into transformed cells led to high-level Bcl-6 protein expression in the nucleus, while BCL6 mRNA levels in clinical materials of diffuse large B-cell lymphoma (DLBCL) with non-Ig ; BCL6 translocations were unexpectedly low. A comparative study suggested that non-Ig ; BCL6 translocation and a low level of BCL6 mRNA expression are concordant indicators of a poor clinical outcome in cases of DLBCL. The coexistence of a non-Ig ; BCL6 translocation with t (14 ; 18)(q32 ; q21) in a single clone did not significantly affect the clinical features of follicular lymphoma. The pathogenetic and clinical implications of non-Ig ; BCL6 translocations in B-NHL subtypes may not be identical to those of Ig ; BCL6. 〔J Clin Exp Hematopathol 46(2) : 43-53, 2006〕 
INTRODUCTION
Chromosomal translocations and rearrangements of oncogenes located at breakpoints are observed in a large proportion of patients with non-Hodgkin's lymphoma of B-cell type (B-NHL). These genetic aberrations, in general, involve immunoglobulin (Ig) gene loci as a partner 1 . As a result of the translocation, the oncogene is transcriptionally deregulated under the influence of the juxtaposed Ig regulatory sequences. t (3 ; 14)(q27 ; q32) and its variants t (2 ; 3)(p11 ; q27) and t (3 ; 22)(q27 ; q11), involving Ig heavy chain (IgH), k light chain (IgLk) and l light chain (IgLl) genes, respectively, were first reported to be detected in 6.3% of cytogenetically analyzed B-NHLs 2 . By analogy with previously wellcharacterized translocations, an oncogene was expected to be located at 3q27, and three groups independently cloned BCL6 (B-cell CLL/ lymphoma 6) gene on this particular chromosomal band [3] [4] [5] . A group at Columbia University headed by Dr. Dalla-Favera very recently engineered transgenic mouse strains harboring a BCL6 gene driven by the IgH Im promoter, mimicking t (3 ; 14)(q27 ; q32), using the knock-in strategy 6 . The mice at between 15 and 20 months of age developed B-cell tumors showing features of diffuse large Bcell lymphoma (DLBCL) at a frequency of 36% to 62%, confirming clearly the oncogenetic role of Ig ; BCL6 translocations in the pathogenesis of B-NHL.
In contrast to other B-NHL-specific translocations, 3q27/ BCL6 translocation is unique in that it can involve not only Ig gene loci but also non-immunoglobulin (non-Ig) chromosomal loci as a partner 7 . Molecular cloning of these translocations revealed that a gene is located at each partner locus and rearranged with BCL6 so that the normal regulatory sequences of BCL6 are replaced with those of the partner gene 7, 8 . Some of these translocations are not random but recurrent, indicating that non-Ig ; BCL6 translocations as well as Ig ; BCL6 play a pathogenetic role in B-NHL. In this review, I first describe the molecular anatomy of non-Ig ; BCL6 translocaextent non-Ig ; BCL6 translocations affect the level of Bcl-6 protein expression. Finally, I discuss the clinical implications of this unique type of translocation in subtypes of B-NHL.
THE BCL6 GENE AND ITS PRODUCT
The BCL6 gene spans 24, 310 bases and contains 11 exons, generating 4 types of splicing patterns (http : //www.genecards.org/cgi-bin/carddisp?BCL6). The ATG signal for the initiation of protein synthesis is within exon 3 and is followed by an open reading frame. The 3q27/BCL6 translocation occurs within the major translocation cluster (MTC) spanning the non-coding exon 1 and intron 1 ; in a majority of cases, breakpoints are located immediately 3′ of exon 1 3, 5, 9 . The translocation, therefore, does not interrupt the proteincoding region of BCL6.
The Bcl-6 protein, consisting of 706 amino acids with a calculated molecular weight of 78,846 Da, is a sequencespecific transcription factor that can repress transcription from promoters containing its DNA-binding site (Fig. 1) 
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. The Cterminal region of Bcl-6 contains six C2-H2 type zinc fingers, each separated by a conserved stretch of seven amino acids. The two cysteine and two histidine residues coordinate a zinc ion and fold the domain into a finger-like projection that can interact with DNA.
The BTB/POZ domain (broad-complex, tramtrack, and bric-a-brac/pox virus and zinc finger) at the N-terminus is a conserved 120-amino acid motif, which is found in 5 to 10% of zinc finger proteins 11 . The primary function of the BTB/ POZ domain appears to be the mediation of protein-protein interactions. It has been shown that the repressive effect of Bcl-6 on the target gene is exerted via the recruitment of SMRT (silencing mediator of retinoid and thyroid receptor), NCoR (nuclear receptor corepressor) and BCoR (BCL6 corepressor) corepressors [12] [13] [14] [15] . Crystallographic analysis of the BTB/POZ domain revealed that it forms a butterflyshaped homodimer to generate a 'lateral grove' motif that interfaces with a 17-residue sequence (BBD motif, Bcl-6 binding domain) of SMRT 12, 15 . A fusion protein that contains the HIV-TAT protein transduction domain and the BBD sequence can penetrate the cell membrane and bind to Bcl-6, thereby blocking the BTB/POZ-mediated recruitment of SMRT 16 . The middle portion of Bcl-6 contains a second domain required for the repressive transcriptional activity (Fig. 1) . Bereschchenko et al. 17 showed that the KKYK motif within the PEST sequence is targeted by p300-mediated acetylation. This post-translational modification disrupts the ability of Bcl-6 to recruit histone deacetylase (HDAC), thereby hindering its capacity to repress transcription.
Targeted inactivation of BCL6 in the mouse germline leads to impaired production of secondary IgG antibody against T-cell-dependent antigens and the spleen of the BCL6 −/ − mouse lacks germinal center (GC) formation [18] [19] [20] . A cDNA array analysis along with loss-of-function experiments revealed a set of genes that are negatively regulated by Bcl-6 21 . The BLIMP1 (B-lymphocyte-induced maturation protein 1) gene, which is a representative target gene, plays a key role in the differentiation of B-cells into plasma cells by turning off the entire mature B-cell gene expression program 22, 23 . It is presumed that BCL6 is the master gene for the generation by B-cells of a GC, acting to modulate the transcription of genes involved in cell proliferation, differentiation and apoptosis.
MOLECULAR ANATOMY OF NON-IG ; BCL6 TRANSLOCATIONS
To determine the partner of the BCL6 translocation, two polymerase chain reaction (PCR)-based approaches have been applied, i.e. 5′-rapid amplification of cDNA ends (5′-RACE) and long-distance inverse (LDI-) PCR (Fig. 2) 9,24,25 . Both methods isolate sequences adjacent to the junction, a database search of which leads to identification of the partner gene. Table 1 lists non-Ig partners that have been identified to date 9, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . These include the genes for a transcription factor, serine/threonine-protein kinase, cytokine receptor, Ras small GTPase, heat shock proteins and so on. In spite of this marked diversity of protein products, there are common features in the molecular anatomy of non-Ig ; BCL6 translocations. First, the gene fusion occurs in the same transcriptional orientation ; second, the breakpoint on the partner gene is located in close proximity to the promoter sequence ; and third, the complete sequence of the promoter is fused upstream of the coding region of BCL6 on the der(3) chromosome ( Fig. 3) . As the result of translocation, many types of regulatory sequences of each partner gene substitute for the 5′ untranslated region of BCL6, and the rearranged BCL6 comes under the control of the replaced promoter (promoter substitution 36 ). The translocated allele generates chimeric transcripts composed of 5′ sequences of the partner followed by the open reading frame of BCL6, which is readily detectable by reverse transcriptase-mediated PCR 33, 37 . Although the transcriptional control of these non-Ig genes has not been fully determined, it should be noted that some genes are transcriptionally activated by a variety of stimuli, including cell cycle control (H4), changes in the physical environment (HSP89a and HAP90b) 38 , and response to cytokines (PIM1 and CIITA). Considering that GC Bcells, in which the BCL6 translocation is presumed to occur, proliferate rapidly in response to antigen, it is likely that a BCL6 gene affected by the translocation is inappropriately expressed during B-cell proliferation.
There is evidence to suggest that the somatic hypermuta- The breakpoints on the BCL6 gene were within the MTC region, while those on the HSP genes were either 5′ or 3′ of the translation initiation sites. Transcriptional control of HSP genes is mediated by three tandem copies of heat shock element (HSE). In response to heat shock, the heat shock factors as a trimer bind to these HSEs 38 . As the result of translocation, the complete set of the HSEs is fused upstream of BCL6. Therefore, the expression of BCL6 apparently comes under the control of the heat shock factors that bind to the HSEs [39] [40] [41] . The mutations are clustered within the first exonintron boundary of the gene, which overlaps with the MTC 42 , suggesting that SHM and translocations involving BCL6 are mediated by common molecular mechanisms. On the other hand, PIM1 and RHOH, both of which are non-Ig partners (Table 1) , are mutated in DLBCL and the regions involved in the mutation match those in the translocation 43 . These observations suggest that the SHM machinery, which generates double-stranded breaks of DNA, targets both the BCL6 and non-Ig partners of GC-B-cells, thereby predisposing these genes to exchanges of genetic material.
DEREGULATED EXPRESSION OF BCL-6 PRO-TEIN BY HISTONE H4; BCL6 TRANSLOCATION
We showed that t (3 ; 6)(q27 ; p21) results in the fusion of BCL6 with a particular histone H4 gene (HUGO nomenclature : HIST1H4I) on 6p21 27 . The H4 gene is composed of a single exon followed by a terminal palindrome.
Transcriptional control of the histone H4 gene is mediated by two multipartite proximal promoter elements (Sites I and II), the activity of which is augmented by two distal domains (Sites III and IV) 44 . The Site II-equivalent of the H4 gene contains consensus binding sites for the transcription factors HiNF-M, HiNF-D and HiNF-P. These Site II-binding proteins, in addition to other co-regulatory molecules, contribute to enhancing the H4 gene transcription at the G1/ S phase transition 44 . On the other hand, the terminal palindrome sequence initially contributes to cleavage of the primary H4 gene transcript and mediates mRNA destabilization at the end of S phase 45 . The sequence approximately 16 bp downstream of the palindrome is also essential and through base-pairing interactions mediates the U7 snRNP-dependent processing of the mRNA 3′ end 45 . We cloned 5 H4 ; BCL6 fusion genes and found that the breakpoints on H4 were distributed within the 3′ half of the H4 protein-coding region or in the vicinity of the palindrome 37 . Therefore, the mechanism of 3′ end formation of H4 is perturbed and the resulting fusion mRNAs with BCL6 are predicted to be processed like normal polyadenylated mRNAs. It appears then that the deregulation of Bcl-6 protein expression is facilitated by 'capturing' sequences that support cell cycle control of H4 gene transcription during the To determine the level of Bcl-6 protein expression directed by the H4 ; BCL6 fusion gene as compared with the germ-line BCL6, we constructed expression plasmids that mimicked the structure of t (3 ; 6)(q27 ; p21) (Fig. 4A ) 37 . Transient transfection of the plasmids into COS-7 cells resulted in transcription of H4 ; BCL6 fusion mRNA that had the same structure as mRNA from clinical materials with t (3 ; 6)(q27 ; p21). Comparison of the levels of Bcl-6 expression revealed that H4 ; BCL6-transfected cells produced markedly more Bcl-6 than cells transfected with a plasmid carrying BCL6 driven by its normal promoter (Fig. 4B) . We next subjected the COS-7 cells to indirect immunofluorescence microscopy using a polyclonal antibody against Bcl-6 and found that H4 ; BCL6-transfected cells displayed bright nuclear staining with a characteristic granular pattern (Fig. 4C) ; the granules have been shown to contain SMRT and N-CoR co-repressors 13 . The introduction of a series of deletion mutants that lacked the Site II sequences led to a reduction in the expression of Bcl-6 to the basal level (Fig. 4C) . These findings indicate that H4 ; BCL6 gene fusion leads to enhanced Bcl-6 protein expression, which is promoted by the H4 regu- Fig. 4 . Construction of H4 ; BCL6 fusion gene mimicking t(3 ; 6)(q27 ; p21) and the effect of transfection into COS-7 cells 37 . (A) Diagram of the Bcl-6-expression plasmids driven by the SV40 promoter, normal BCL6 promoter, and H4 ; BCL6 fusion gene of case no. 457. Transcription initiated from the H4 ; BCL6 fusion gene was contiguous with the BCL6 exon2 at the cryptic 5' splice-donor site ( ▲ ). A series of deletion mutants of the last fragments was generated by digestion with exonuclease III and mung bean nuclease. IRF2, interferon regulatory factor 2 ; B, BamHI ; X, XbaI ; H, HindIII ; G, BglII ; and S, SacI. fold under-expressed in the former cells as compared with the latter reference cells (Fig. 4D) . The down-regulated genes included BLIMP1 and cyclin D2 (CCND2), both of which are primary target genes negatively regulated by Bcl-6 21 . These experiments provided clear evidence that the H4 ; BCL6 translocation leads to high-level Bcl-6 expression, thereby repressing the transcription of the target genes.
PROGNOSTIC SIGNIFICANCE OF NON-IG ; BCL6 TRANSLOCATIONS IN DLBCL
The correlation between BCL6 translocations and clinical features of DLBCL has been a subject of controversy. An earlier study showed that BCL6 rearrangements determined by Southern blotting occurred more frequently in extranodal DLBCL than in node-based diseases and correlated with a favorable clinical outcome 46 . However, later studies failed to find a statistically significant impact of BCL6 translocations on the clinical outcome of DLBCL [47] [48] [49] [50] . We studied whether the partner in BCL6 translocations influences the clinical behavior and/ or treatment outcome of DLBCL 47, 51 . Of 43 DLBCL patients having BCL6 abnormalities, 26 had Ig ; BCL6 translocation, while 15 had non-Ig ; BCL6. The remaining 2 had a deletion of a > 1 kb segment encompassing exon 1 of BCL6. Although there were no significant differences in pretreatment clinical features between the 26 patients with Ig ; BCL6 translocation and the 17 patients with non-Ig ; BCL6, including the 2 with a deletion, overall survival (OS) of the non-Ig ; BCL6 group was inferior to that of the Ig ; BCL6 group (Fig. 5A) . Fourteen patients of the non-Ig ; BCL6 group died within 2 years, while 5 patients of the Ig ; BCL6 group have been disease-free for some time. The estimated 2-year OS of the Ig ; BCL6 and non-Ig ; BCL6 groups was 58.1% and 17.6% (P＝0.003), respectively. Although the total number of patients analyzed was quite small, our study suggested that non-Ig ; BCL6 translocation is an indicator of poor prognosis in DLBCL, and additional studies of larger patient populations are warranted.
A cDNA microarray analysis revealed that DLBCL patients with the GC B-cell-like (GCB) pattern of gene expression have a significantly better OS than those with the activated B-cell-like (ABC) expression profile 52 . BCL6 is a representative gene of the GCB-type signature and high-level expression of BCL6 at both the mRNA and protein levels has been shown to be a predictor of a favorable treatment outcome in cases of DLBCL 53, 54 . To address the relationship between our finding that DLBCL with non-Ig ; BCL6 translocation has a worse prognosis than DLBCL with Ig ; BCL6 and the fact that the level of BCL6 expression is related to clinical outcome, we compared the levels of BCL6 mRNA between the two groups. The amount of mRNA measured by real-time quantitative PCR was divided by that of the GAPDH gene, and the BCL6-GAPDH value was normalized to that of Raji cells. A comparative study showed that the BCL6 mRNA levels of the Ig ; BCL6 group (n ＝ 6 ; range, 2.7-7.0 ; mean, 4.3) were significantly higher than those of the 51 , and the level of the latter group was below the threshold (＝ 1.3) for a poor prognosis determined by Lossos et al 54 (Fig.  5B) . This observation suggests that high versus low-level BCL6 mRNA expression and an Ig versus non-Ig partner of BCL6 translocation are concordant prognostic indicators of DLBCL. Further study is required to determine whether Ig ; BCL6 and non-Ig ; BCL6 translocations correspond to GCB and ABC-type DLBCL, respectively.
REARRANGEMENTS OF BCL6 CONCURRENT WITH THOSE OF C-MYC AND/OR BCL2 IN B-NHL
Since the 3q27 translocation is the sole cytogenetic abnormality in some cases of B-NHL, the translocation and/or BCL6 rearrangements may be primarily involved in the development of B-NHL. However, 3q27/BCL6 translocation sometimes coexists with other translocations in a single clone 55, 56 , including t (8 ; 14)(q24 ; q32) and t (14 ; 18)(q32 ; q21) involving c-MYC and BCL2, respectively, making the role of the 3q27/BCL6 translocation in the pathogenesis of B-NHL unclear.
We conducted a series of LD/LDI-PCR assays, which readily detect rearrangements involving c-MYC, BCL2 and BCL6 9, 57, 58 , using clinical materials of B-NHL, and found that a total of 14 patients carried a rearrangement of BCL6 concurrently with rearrangements of c-MYC and/ or BCL2 ; 10 patients had both BCL2 and BCL6 rearrangements, 3 had both c-MYC and BCL6 rearrangements, and the remaining patient had rearrangements of all 3 genes ( Table 2 ). The constant genes affected by c-MYC ; IgH, which is the molecular equivalent of t (8 ; 14)(q2 ; q32), were Cg. The BCL2 genes in 10 patients were rearranged at the 3′, i.e. from the major breakpoint cluster region (MBR) through to the minor cluster region (mcr), while 1 patient had a 5′ breakpoint 59 . BCL6 translocations involved Ig genes as partners in 5 patients, and non-Ig genes as partners in 8 patients. The remaining patient had a deletion of a 1.2-kb segment within the MTC region of BCL6 9 . Seven of the 10 patients with both BCL2 and BCL6 rearrangements had follicular lymphoma (FL), while all of the 4 patients with c-MYC rearrangement had DLBCL. In particular, of 7 FL patients, 5 had a non-Ig ; BCL6 translocation ; they had advanced-stage disease at presentation and 3 were positive for CD10 expression. All but one patient with FL showed indolent clinical behavior, although initial treatment with a doxorubicin-containing regimen failed to achieve a complete clinical response. Thus, in contrast to the general consensus that multiple translocations can occur at the time of transformation from low-to high-grade disease, the coexistence of a non-Ig ; BCL6 translocation with a BCL2 rearrangement did not significantly affect the clinical features of FL defined by t (14 ; 18)(q32 ; q21). In contrast, the pretreatment parameters as well as treatment outcome of DLBCL patients varied. Thus, a dual/triple rearrangement does not necessarily result in synergic effects on the malignant phenotype of B-NHL subtypes.
CONCLUSION
We showed that the introduction of expression plasmids mimicking the non-Ig ; BCL6 fusion genes into transformed cells led to high-level Bcl-6 protein expression in the nucleus 33, 37, 60 . In contrast, the BCL6 mRNA levels of DLBCL cells carrying a non-Ig ; BCL6 translocation were unexpectedly low 37, 51 . It is presumed that the BCL6 gene of a B-cell carrying a non-Ig ; BCL6 translocation is over-expressed in the GC-microenvironment, thereby triggering neoplastic transformation. However, such a transcriptional activation would be transient and, once the neoplastic B-cell gains a growth advantage over normal cells, the expression would be down-regulated (Fig. 6) . We next showed that the coexistence of a non-Ig ; BCL6 translocation with other translocations does not necessarily have a significant impact on the clinical features of B-NHL subtypes. Thus, there may be a hierarchical order to the rearrangement of oncogenes that ultimately determines the characteristics of B-NHL. Our findings suggested that the pathogenetic and clinical implications of non-Ig ; BCL6 translocations in B-NHL may not be identical to those of Ig ; BCL6. 
